Meet us at ASCO 2025
Meet us at ASCO 2025
- McCormick Place Convention Center | Chicago, IL
- May 31 - Jun 2, 2025
- Booth #IH02
Derisk ADC Development with AI-powered Quantitative Continuous Scoring (QCS) and Spatial Proximity Analysis
Antibody drug conjugates (ADCs) hold great promise in oncology, but tumor heterogeneity and the complex mechanism of action (MOA) of the drug and evolving resistance mechanisms present a significant challenge for development.
Let’s explore how AI spatial proteomics and OD-based quantitative scoring of IHC assays can help you derisk your ADC programs.
Demo our AI-powered Spatial Inference Platform for Qualifying ADCs and Bispecific Therapeutic Targets
We’ve built a comprehensive analysis studio so you can leverage multiplex imaging and pathology data to map target distribution and heterogeneity, quantify the bystander effect, assess off-target toxicity and immunogenicity risk, and design biomarker-informed clinical trials.
Immunotherapy Poster Session
Application of a novel multiplex imaging-based immunotherapy panel and AI-powered analysis solution for predictive spatial biomarker identification on immunotherapy-treated melanoma patients.
We've Launched a First-of-its-Kind Deep Learning Model To Automate Spatial Proteomics Analysis
We’ve developed a new deep learning model that automates and standardizes a critical bottleneck in analyzing multiplex immunofluorescence (mIF) data. This brings us one step closer to discovering and validating spatial biomarkers across samples, different antibody markers, and across study cohorts.
Our ASCO On-site Team
Dr. Ken Bloom
Head of Pathology
Jonathan Daniels
SVP Strategy & BD
Byron Lawson
Vice President, Pharma Business Development
Grainger Greene
Head of Product
Neelima Kumar
Senior Director of Marketing
Book a demo or meeting with us
Please complete the form below to schedule a meeting with our team at ASCO 2025: